Additional undisclosed solid tumor programs

About ArsenalBio

ArsenalBio is a privately held, clinical-stage biotech focused on next-generation programmable cell therapies for solid tumors. With $325 million in funding and a multi-program partnership with Bristol Myers Squibb, its proprietary CITE (CRISPR Integration of Transgene via Electroporation) platform enables precise, single-site genomic insertion of large synthetic modules, such as dual-antigen logic gates. The company aims to address key CAR T limitations—tumor infiltration, persistence, and the immunosuppressive tumor microenvironment—through a computationally driven, iterative discovery engine. Lead candidates are in Phase 1 trials for solid tumors, with an initial focus on achieving tumor-specific killing while sparing healthy tissue.

Therapeutic Areas

Other Solid tumors Drugs